33 / 37
Page 88
Notes:
conferenceseries
.com
Volume 9, Issue 9 (Suppl)
J Cancer Sci Ther, an open access journal
ISSN: 1948-5956
World Cancer 2017
October 19-21, 2017
25
th
WORLD CANCER CONFERENCE
October 19-21, 2017 | Rome, Italy
J Cancer Sci Ther 2017, 9:9(Suppl)
DOI: 10.4172/1948-5956-C1-112
Systematical administration of
Clostridium ghonii
spores results in significant tumour regression and
strong antitumour Th1 responses in TC-1 tumour bearing mice
Ming Q Wei, Guoying Ni, Xiaosong Liu
and
David Good
Griffith University, Australia
U
p to 85% of solid cancers, once diagnosed, lost the opportunity to be operable. These cancers have anoxia regions that
limit the effectiveness of conventional therapies, which however, provide a heaven for anaerobic bacteria. Our laboratory
has adapted the spores of an extracellular
Clostridium ghonii
strain that caused targeted oncolysis by selectively germinating,
multiplying and digesting away of the solid cancer extramatrics, cellular structure, and cancer cells, resulting in significant
enhanced tumour regression. Other anaerobic bacteria also showed a Toll-like receptor 4-mediated an antitumor host response
together with significant increases of intra-tumour IFNγ, CXCL9 andCXCL10 levels as well as more infiltration of macrophages,
neutrophils, CD4+ and CD8+ T cells in C3H/HeN mice. In this report, we exployed a HPV E7 transformed TC-1 cell tumour
bearing mice as a model and demonstrated that intratumoural and/or introvenous administration of a strain of a deviriative
of
Clostridium ghonii
(DCG) spore leads to a significant tumour regression and a tumour local pro-inflammatory response
characterized with increased levels of IL-6, IL-17 and IFNγ. IFNγ secreting T cells are also attracted to the tumour site. Low
numbers of antigen specific T cells were elicited after DCG treatment are elicited by intravenous DCG treatment. The results
suggested that both oncolytic effects and the anticancer immune respnses are contriuting to cancer regression. Furthermore,
strategies for optimium combined oncolytic, ie.: oncotic therapy, if combined with a therapeutic vaccine, more antigen specific
T cells may be attracted to the tumour site and therefore, may achieve better outcome for cancer treatment.
m.wei@griffith.edu.au